Literature DB >> 8537362

Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.

Z Gu1, Y Quan, Z Li, E J Arts, M A Wainberg.   

Abstract

We have employed a cell-free human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) assay to study the effects of non-nucleoside inhibitors of RT (NNRTI) by directly monitoring specific HIV DNA products using a HIV-1 genome-derived template and an oligodeoxynucleotide primer. As previously shown by ourselves and others, nucleoside analog triphosphates, e.g. 3'-azido-3'-deoxythymidine triphosphate and 2',3'-dideoxyadenosine triphosphate, could directly inhibit HIV RT RNA-dependent DNA polymerase activity by causing chain termination, as visualized in a RT reaction that yields specific DNA products. In contrast, each of two NNRTIs, nevirapine and delavirdine, directly inhibited RT activity without causing chain termination effects. We also analyzed interactions between nucleoside analogs and NNRTIs or among NNRTIs by chain elongation/dNTP incorporation and/or steady-state kinetic assays. Combinations of nevirapine with the triphosphates of either the (-)-strand of 2',3'-dideoxy-3'-thiacytidine or 2',3'-dideoxyadenosine yielded additive/synergistic effects on RT activity. However, only an additive effect was observed when combinations of nevirapine and 3'-azido-3'-deoxythymidine triphosphate were employed. Combinations of nevirapine and delavirdine had an antagonistic effect on the inhibition of HIV-1 RT activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537362     DOI: 10.1074/jbc.270.52.31046

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Analysis of the combined effect of two linear inhibitors on a single enzyme.

Authors:  J J Martinez-Irujo; M L Villahermosa; J Mercapide; J F Cabodevilla; E Santiago
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

Review 2.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Z Gu; M A Wainberg; N Nguyen-Ba; L L'Heureux; J M de Muys; T L Bowlin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

5.  [d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.

Authors:  Yassir Younis; Roger Hunter; Clare I Muhanji; Ian Hale; Rajinder Singh; Christopher M Bailey; Todd J Sullivan; Karen S Anderson
Journal:  Bioorg Med Chem       Date:  2010-05-11       Impact factor: 3.641

6.  Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Authors:  Z Gu; X Li; Y Quan; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

7.  HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.

Authors:  Kalyan Das; Sergio E Martinez; Joseph D Bauman; Eddy Arnold
Journal:  Nat Struct Mol Biol       Date:  2012-01-22       Impact factor: 15.369

8.  First complete-genome documentation of HIV-1 intersubtype superinfection with transmissions of diverse recombinants over time to five recipients.

Authors:  Yang Gao; Shan He; Wen Tian; Dan Li; Minghui An; Bin Zhao; Haibo Ding; Junjie Xu; Zhenxing Chu; Hong Shang; Xiaoxu Han
Journal:  PLoS Pathog       Date:  2021-02-12       Impact factor: 6.823

9.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602

10.  Frequent intra-subtype recombination among HIV-1 circulating in Tanzania.

Authors:  Ireen E Kiwelu; Vladimir Novitsky; Lauren Margolin; Jeannie Baca; Rachel Manongi; Noel Sam; John Shao; Mary F McLane; Saidi H Kapiga; M Essex
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.